Science2 distinct publishers2 min readPublished
Harvard's Church lab reports AGENTEX in Nature: engineered tRNAs and ribosomes in a cell-free mix. Nobody has to recode an organism to prototype a genetic code any more.
The Scientist · Science desk

Compiled by The ScientistSomething wrong?How this is made
Every tRNA ends in the same three bases, and the ribosome checks for them. Bases G2251 and G2553 in the 23S rRNA of the E. coli ribosome pair with that 3' CCA end [4], and those Watson-Crick contacts in the large subunit are what stop a tRNA carrying any other 3' sequence from being accommodated during translation [3]. Change the subunit and you have changed the lock rather than the genome: pools of odd-ended tRNAs can then specify a code of their own on ribosomes built to accept them [22].
The reason to bother is a housekeeping problem in cell-free translation. Lysate systems, made from crude cell extracts, keep the host's translation and modification enzymes and scale for bioproduction, but they also carry the host's complete tRNA set, which crosstalks with any reassigned sense codon [11]. The tidy alternative, PURE, rebuilds the reaction from individually purified components, which is where most proof-of-concept code expansion has been done, and it is the poorer choice at preparative scale [12]. A ribosome that will not accept CCA ends renders the host's own tRNAs invisible to it, so the lysate can stay in the tube.
The load-bearing surprise sits one step upstream, at charging. The team found the tRNA 3' end far more tolerant of mutation than assumed, with most odd-ended tRNAs still aminoacylated by all of E. coli's natural synthetases [5]. Code expansion has until now leaned on engineered synthetases alongside engineered ribosomes and tRNAs [14]. Here the enzymes arrive as found, which is the part that removes work rather than adding a step.
Where 34 comes from is worth doing on paper. The standard code spends 64 codons on 20 canonical amino acids [10]; compress it to 20 sense codons plus one start and one stop, and 14 codons come free for non-standard building blocks [8]. Twenty plus fourteen is the 34 [9]: the natural alphabet kept, with fourteen open slots beside it. Church puts the old rate at a decade per amino acid added [18], and his lab's own record, nine years to free the first codon and ten more for the second, works out at about nine and a half years each [17].
The point of fourteen slots is not one exotic residue in one protein. More than 400 non-standard amino acids have already been installed in proteins in living cells [13]. What has not worked is several of them in a single chain at high purity [15], and that, rather than a slightly decorated enzyme, is what a compressed code and an automated, multiplexed prototyping loop [2] are pointed at.
Ranked by verification strength, evidence, and original report placement.
The team discovered that the tRNA 3' end shows remarkable flexibility to mutation, allowing aminoacylation of most non-CCA-3' tRNAs (otRNAs) by all Escherichia coli aminoacyl tRNA synthetases.
The authors developed cell-free translation systems enabling compressed genetic codes of 34 aaRSs for 34 codons.
The lab of geneticist George Church at Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering devised AGENTEX, published in Nature; it lets researchers custom-engineer tRNAs and ribosomes and insert them into a standard lab concoction containing cell components but no actual cells, where they make new proteins without requiring genome recoding or any organisms, and without interfering with natural protein-making machinery.
AGENTEX stands for automated genetic tRNA expansion, a method for multiplexed robotic prototyping of genetic codes in cell-free translation systems.
Two Watson-Crick interactions in the ribosomal large subunit mediate recognition of the 3' CCA end of tRNAs, preventing tRNAs with alternative 3' sequences from being accommodated during translation.
The interaction is between the 3' CCA sequence of all tRNAs and bases G2251 and G2553 in the 23S rRNA of the Escherichia coli ribosome.
Follow any of these and your For You feed starts watching them — no settings page required.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Peer-reviewed primary paper with named mechanism and stated scope
The core factual spine - the G2251/G2553 CCA-recognition mechanism, otRNA aminoacylation by all E. coli aaRSs, 34-aaRS/34-codon cell-free systems, and the two-code, up-to-three-codon evaluation - comes from a Nature research article that also states its own limits and contradicts prior in vitro reports explicitly. The secondary source is an institutional release restating the same work. Evidence is strong for the mechanism and the workflow, weaker for the comparative speed and safety assertions, which are quoted rather than measured, and there is no independent replication in the supplied material.
Originating-lab demonstration only
Supplied sources show a publication event, an institutional announcement, and one in-house evaluation reassigning up to three codons. No external laboratory, company, licensee, or production use appears anywhere in the material, and no yields or run volumes are disclosed. Adoption is therefore real but confined to the originating lab at the moment of publication.
Capability headline runs ahead of demonstrated scope
The public framing - 34 customizable codons, proteins with up to 34 amino acids, 'the door to 34 at once', thousands of molecules built and evolved in parallel - describes designed capacity. The paper's own demonstrated result is two genetic codes with non-standard amino acid incorporation and reassignment of up to three codons, and the paper discloses a lysate host-tRNA crosstalk problem the release omits. The underlying mechanism and the dogma reversal are solid, so the gap is one of scope inflation rather than fabrication; the Nature abstract itself is appropriately bounded.
Announcement carried entirely by originating-lab voices
The secondary coverage is an institutional announcement in which every evaluative statement comes from the paper's first author or senior author, both at HMS and the Wyss Institute, and it frames downstream value across medicine, agriculture, materials science and environmental remediation. That is a clear promotional incentive around a career-defining result. The supplied sources disclose no funding, commercial, licensing or equity interest, so the score reflects visible institutional promotion only and not any financial conflict.
High on mechanism and scope, low on uptake and comparative gains
Two sources describe one event, one of them a peer-reviewed primary paper that states its own experimental bounds, so the mechanism, the compression arithmetic and the demonstrated scope are held with high confidence. Confidence is reduced by the single-event, two-publisher cluster, the absence of any independent voice or external user, the truncated paper excerpt, and the fact that the speed, safety and scale-up claims rest on author assertion.
science
A phage kinase with no target list: EMBL finds one enzyme that breaks several bacterial defences1 distinct publisher
security
Sixteen of 285 AI-Designed Phages Were Viable, and Screening Moves to the Synthesis Order1 distinct publisher
science
One pot, 1,000 gene fragments: the DNA writing bottleneck starts to move1 distinct publisher
science
HIPAA Covers Less Than You Think, And "Anonymized" Is Not A Legal Shield1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.
nature.com
1 article · August 25, 2026
phys.org
1 article · August 26, 2026